Systemic pharmacological treatments for chronic plaque psoriasis: A Systematic Review and an Individual-Patient Data Network Meta-Analysis of Randomized Controlled Trials

Systemic pharmacological treatments for chronic plaque psoriasis: A Systematic Review and an Individual-Patient Data Network Meta-Analysis of Randomized Controlled Trials

Psoriasis is a skin disease that causes red, itchy, scaly patches, commonly on the knees, elbows, trunk, and scalp. It is a long-term and incurable disease. Drugs are used to manage the symptoms. These drugs are called systemic treatments, as they act on the whole body. They are generally taken by mouth (oral) or injected. There are three different classes of systemic treatments to treat psoriasis: non-biologic agents, small molecules, and biologics. To determine the benefits and harms of taking systemic treatments for psoriasis and whether some treatments are more effective than others, we searched for studies that tested systemic treatments for plaque psoriasis. Then, we compared all the drugs with each other using a statistical method called network meta-analysis (NMA). We found 158 RCTs with 57,831 adult people. The biologics treated psoriasis better than the small molecule and non-biologic drugs. However, the results of the included studies used are presented as a mean for all included patients and not at the individual patient level. We need to know now which treatment(s) is (are) the most effective in a specific patient. For example, which would be the better treatment for someone overweight or someone who has not been improved with a given previous treatment. For this purpose, it is mandatory to perform the same analysis (NMA) based on individual patient data. This is the aim of this project.

[{ "PostingID": 3953, "Title": "NOVARTIS-CAIN457A2211", "Description": "A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis" },{ "PostingID": 3955, "Title": "NOVARTIS-CAIN457A2220", "Description": "A Randomized, Double-blind, Placebo Controlled, Multicenter Dose Ranging Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis" },{ "PostingID": 3956, "Title": "NOVARTIS-CAIN457A2302", "Description": "A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis" },{ "PostingID": 3957, "Title": "NOVARTIS-CAIN457A2303", "Description": "A Randomized, Double-blind, Double-dummy, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, Compared to Placebo and Etanercept, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis" },{ "PostingID": 4068, "Title": "NOVARTIS-CAIN457A2304", "Description": "A randomized, double-blind, multicenter study of subcutaneous secukinumab, assessing Psoriasis Area and Severity Index (PASI) response and maintenance of response in subjects with moderate to severe chronic plaque-type psoriasis on either a fixed dose regimen or on a retreatment at start of relapse regimen Study Comparing secukinumab Use in Long-term Psoriasis maintenance therapy: fixed regimens vs reTreatment Upon start of RElapse (SCULPTURE" },{ "PostingID": 4070, "Title": "NOVARTIS-CAIN457A2308", "Description": "A randomized, double-blind, placebo controlled, multicenter study of subcutaneous secukinumab in prefilled syringes to demonstrate efficacy after twelve weeks of treatment, and to assess the safety, tolerability, usability and long-term efficacy in subjects with chronic plaque-type psoriasis" },{ "PostingID": 4071, "Title": "NOVARTIS-CAIN457A2309", "Description": "A randomized, double-blind, placebo controlled, multicenter study of subcutaneous secukinumab in autoinjectors to demonstrate efficacy after twelve weeks of treatment, and to assess the safety, tolerability, usability and long-term efficacy in subjects with chronic plaque-type psoriasis" },{ "PostingID": 20264, "Title": "NOVARTIS-CAIN457A2317", "Description": "A 52-week, multicenter, randomized, double-blind study of subcutaneous secukinumab to demonstrate efficacy as assessed by Psoriasis Area and Severity Index at 16 weeks of treatment compared to ustekinumab and to assess long-term safety, tolerability and efficacy in subjects with moderate to severe plaque psoriasis (CLEAR)" },{ "PostingID": 20265, "Title": "NOVARTIS-CAIN457A2326", "Description": "A 52-week, randomized, double-blind study of secukinumab (300 mg) compared to ustekinumab in subjects with moderate to severe plaque psoriasis" },{ "PostingID": 20267, "Title": "NOVARTIS-CAIN457A2313", "Description": "A randomized, double-blind, placebo-controlled, multicenter, study to demonstrate the efficacy at 16 weeks of secukinumab 150 and 300 mg s.c. and to assess safety, tolerability and long-term efficacy up to 132 weeks in subjects with moderate to severe nail psoriasis" },{ "PostingID": 20928, "Title": "NOVARTIS-GP17-301", "Description": "A Randomized, Double-blind, Multicenter Study to Demonstrate Equivalent Efficacy and to Compare Safety and Immunogenicity of a Biosimilar Adalimumab (GP2017) and Humira® in Patients With Moderate to Severe Chronic Plaque-type Psoriasis" },{ "PostingID": 21017, "Title": "NOVARTIS-GP15-302", "Description": "Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Etanercept (GP2015) and Enbrel (EGALITY)" },{ "PostingID": 21018, "Title": "NOVARTIS-CAIN457AGB01", "Description": "Secukinumab in Tumor Necrosis Factor (TNF) - Inadequate Response (IR) Psoriasis Participants. (SIGNATURE)" },{ "PostingID": 21019, "Title": "NOVARTIS-CAIN457A2212", "Description": "Multiple-loading Dose Regimen Study in Patients With Chronic Plaque-type Psoriasis" },{ "PostingID": 21020, "Title": "NOVARTIS-CAIN457ADE02", "Description": "Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated With Secukinumab (CARIMA)" },{ "PostingID": 21021, "Title": "NOVARTIS-CAIN457AUS02", "Description": "Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis (VIP-S)" },{ "PostingID": 21022, "Title": "NOVARTIS-CAIN457A2323", "Description": "Study of Secukinumab With 2 mL Pre-filled Syringes (ALLURE)" },{ "PostingID": 21023, "Title": "NOVARTIS-CAIN457A2318", "Description": "Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis" },{ "PostingID": 21024, "Title": "NOVARTIS-CAIN457AUS07", "Description": "Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis Patients (ObePso-S)" },{ "PostingID": 21025, "Title": "NOVARTIS-CAIN457A2324", "Description": "Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis" },{ "PostingID": 21026, "Title": "NOVARTIS-CAIN457A2325", "Description": "Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis (MATURE)" },{ "PostingID": 21027, "Title": "NOVARTIS-CAIN457ADE06", "Description": "Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis. (PRIME)" }]